Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effect of Single High-Dose Vitamin D3 Versus Placebo on Hospital Length of Stay in Children With Severe Pneumonia. (VIT-D-PNEUMONI)

9 november 2026 bijgewerkt door: Adeel Bashir, Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Comparison of the Mean Hospital Length of Stay After Single High Dose of Vitamin D3 Versus Placebo in Children Presenting With Severe Pneumonia at DHQ Mirpur Azad Kashmir

Severe pneumonia is a major cause of morbidity and mortality among children and often requires hospitalization and prolonged medical care. Vitamin D plays an important role in immune regulation and inflammatory responses, and its supplementation may help improve outcomes in respiratory infections. However, evidence regarding its effectiveness in reducing the duration of hospital stay among children with severe pneumonia remains limited.

This randomized controlled trial will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children of either sex, aged 1-16 years, presenting with severe pneumonia will be enrolled through non-probability consecutive sampling. Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded.

Eligible participants will be randomly allocated into two groups using sealed opaque envelopes. Group A will receive a single oral dose of 200,000 IU vitamin D3 dissolved in 10 mL of peanut oil, while Group B will receive 10 mL of peanut oil as placebo. Both preparations will be identical in color, taste, smell, consistency, and container. Participants will be followed until discharge. Hospital length of stay, defined as the period from admission to discharge, will be recorded for each patient. Data will be analyzed using SPSS version 20. Mean hospital length of stay will be compared between the two groups using an independent samples t-test, with p≤0.05 considered statistically significant.

The study aims to determine whether a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia.

Studie Overzicht

Gedetailleerde beschrijving

Pneumonia remains one of the leading causes of morbidity and mortality among children, particularly those under five years of age. Severe pneumonia frequently requires hospitalization, prolonged medical care, and close monitoring. Several host, environmental, and infectious factors contribute to the development and severity of childhood pneumonia, including inadequate breastfeeding, low birth weight, malnutrition, exposure to indoor air pollution, overcrowding, and inadequate immunization. Viral and bacterial infections may also occur simultaneously, contributing to disease severity and clinical complications.

Vitamin D has an important role in regulating immune function and inflammatory responses involved in host defense against infections. It is also considered important for normal lung development and preservation of respiratory function. Previous observational studies have suggested an association between vitamin D deficiency and increased susceptibility to respiratory tract infections. Furthermore, research has explored the potential protective effects of vitamin D supplementation against respiratory infections in children and adults.

Although vitamin D supplementation is a relatively simple and potentially inexpensive intervention, its effectiveness in improving clinical outcomes among children hospitalized with severe pneumonia remains uncertain. Previous studies evaluating vitamin D supplementation in children with pneumonia have reported inconsistent findings. Therefore, further clinical research is required to determine whether vitamin D supplementation can improve recovery and reduce the duration of hospitalization in children presenting with severe pneumonia.

This randomized controlled trial will compare the mean hospital length of stay among children with severe pneumonia receiving a single high dose of vitamin D3 and those receiving placebo. The study will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children will be enrolled, with 57 participants allocated to each group. The sample size has been calculated using OpenEpi software, with a 5% level of significance and 90% power. The mean hospital length of stay in the vitamin D supplementation group and placebo group, based on the pilot study, was 4.90 ± 0.37 days and 5.12 ± 0.46 days, respectively. Non-probability consecutive sampling will be used to enroll eligible participants.

Children of either sex, aged 1-16 years, presenting with severe pneumonia will be included in the study. Severe pneumonia will be identified in children presenting with cough and/or difficulty in breathing of less than three weeks' duration along with one or more of the following findings: respiratory rate of 60 or more breaths per minute in children younger than 2 months, 50 or more breaths per minute in children aged 2-11 months, or 40 or more breaths per minute in children aged 12 months or older; lower chest wall indrawing; increased work of breathing indicated by recessions, grunting, or nasal flaring; oxygen saturation (SpO2) of 92% or less; or a new pulmonary infiltrate on chest radiograph appearing as an opacity with or without an air bronchogram.

Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded from the study.

The study will be initiated after approval from the College of Physicians and Surgeons Pakistan and permission from the institutional ethical review committee. Written informed consent will be obtained from the parents or guardians of eligible children before enrollment. Demographic information, including age and gender, will be recorded for each participant. Eligible participants will be randomly allocated into two groups using sealed opaque envelopes bearing the labels A and B. Group A will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution, whereas Group B will receive 10 mL of peanut oil solution as placebo. Both preparations will be identical in color, taste, smell, consistency, and container.

All participants will be followed during their hospital stay. The duration of hospitalization will be recorded for each participant. Participants will be discharged when they demonstrate clinical improvement, stable vital signs, resolution of key danger signs, and the ability to tolerate oral medications. Hospital length of stay will be defined as the period from the date of hospital admission until the date of discharge and will be recorded in days for both groups.

Data will be collected using a structured proforma. In addition to demographic characteristics and assigned study group, information regarding family monthly income, maternal educational status, type of family (joint or nuclear), and type of residence (house or flat) will also be recorded. The primary outcome will be hospital length of stay, measured in days.

Data will be analyzed using Statistical Package for Social Sciences (SPSS), version 20. Mean and standard deviation will be calculated for quantitative variables, including age and hospital length of stay. The Kolmogorov-Smirnov test will be used to assess the distribution of quantitative variables. Normally distributed quantitative variables will be reported as mean ± standard deviation, whereas non-normally distributed variables will be presented as median and interquartile range. Frequencies and percentages will be calculated for qualitative variables, including gender, family monthly income, maternal educational status, type of family, and type of residence. The mean hospital length of stay will be compared between the two study groups using the independent samples t-test. Effect modifiers, including age, gender, family monthly income, maternal educational status, type of family, and type of residence, will be controlled through stratification. Post-stratification independent samples t-tests will be applied, with a p-value of 0.05 or less considered statistically significant.

The study aims to determine whether administration of a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia. The findings may provide evidence regarding the potential role of vitamin D3 supplementation as an adjunctive intervention in the management of severe childhood pneumonia.

Studietype

Ingrijpend

Inschrijving (Geschat)

114

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Adeel Bashir Dr., MBBS, FCPS PGR
  • Telefoonnummer: +92-311-541437 +92-311-5414375
  • E-mail: adeelbashir775@gmail.com

Studie Locaties

    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 61100
        • Werving
        • Department of Pediatircs, Mohtarma Benazir Bhutto Shaheed Hospital, Mirpur AJ&K
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

1 jaar tot 16 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Children of either sex, between 1-16 years of age, presenting with severe pneumonia will be included in the study.

Exclusion Criteria:

  • Patients with history of tuberculosis.
  • Patients with history congenital heart disease and cleft lip/palate.
  • Patients with history of bronchial asthma.
  • Patients with upper airway abnormality.
  • Patients with history of UTI.
  • Patients with history of malaria, dengue and typhoid fever.
  • Patients with history of malnourishment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Vitamin D3 Group

Participants allocated to this group will receive a single high oral dose of 200,000 IU vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and the duration from admission to discharge will be recorded in days.

Participants allocated to the vitamin D3 group will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.

Placebo-vergelijker: Placebo Group

Participants allocated to this group will receive 10 mL of peanut oil solution as placebo. The placebo preparation will be identical to the vitamin D3 solution in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and the duration from admission to discharge will be recorded in days.

Participants allocated to the placebo group will receive 10 mL of peanut oil solution orally. The placebo preparation will be identical to the vitamin D3 preparation in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Mean Hospital Length of Stay
Tijdsspanne: From hospital admission until discharge (3-14 days).

Hospital length of stay will be measured in days, from the date of hospital admission until the date of discharge. The mean hospital length of stay will be compared between children receiving a single high dose of vitamin D3 and those receiving placebo.

From hospital admission until discharge (3-14 days).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

  • 9. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database Syst Rev 2018(7):23-33. 10. Singh N, Kamble D, Mahantshetti NS. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children. Indian J Pediatr. 2019;86(12):1105-11. 11. Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017 Dec;82(6):986-93. 12. Hurwitz JL, Jones BG, Penkert RR, Gansebom S, Sun Y, Tang L, et al. Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. J Pediatr. 2017;187:323-7.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 juli 2026

Primaire voltooiing (Geschat)

15 november 2026

Studie voltooiing (Geschat)

15 november 2026

Studieregistratiedata

Eerst ingediend

3 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

9 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data (IPD) will not be shared with other researchers. No data-sharing plan has been established for this study. Study data will be used solely for the purposes of the approved research.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren